Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice. - Wikidata - awgldk - TriplyDB

Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice.

Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice.

http://www.wikidata.org/entity/Q45159120

about

Endothelial Progenitor Cells in Diabetic Microvascular Complications: Friends or Foes?Fluorescent microangiography is a novel and widely applicable technique for delineating the renal microvasculature Vascular endothelial growth factor-receptor 1 inhibition aggravates diabetic nephropathy through eNOS signaling pathway in db/db mice Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice Angiogenesis and chronic kidney disease.Diabetic nephropathy - complications and treatment.Diabetic angiopathy and angiogenic defects.Vegfa protects the glomerular microvasculature in diabetes.Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes.Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy.Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes.Antiangiogenic Therapy for Diabetic Nephropathy.Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes.Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease.

P2860

Q26745523-A7303927-CBC0-4E27-813F-382EAF1165CC Q27320632-9CF41CB7-0885-4DF0-B4DA-6A31CBEEB7DF Q31159383-3B5EAC94-2E82-4332-874C-1D347BB1189A Q33995140-4D445D8A-E9E3-4376-B605-856735C52C6F Q34075013-BE185C58-05F0-4060-94A7-B0370344E021 Q34387952-AA6122DC-BC8E-4865-A2DB-7B5CB54033CB Q36301365-347603FB-B8A1-4516-9861-955E34762864 Q36339615-17A0DC14-0F27-4BBD-A68F-5BB0FDB85EE1 Q37154812-0970F81D-B4F0-416F-B053-75E1AB934927 Q37819453-7A8EFAF7-7617-494D-826B-3DB4BE2E0D2C Q38332511-0F489D73-65A3-4F59-AD94-F886CF576768 Q41354182-C7E236A8-E12E-48CF-A718-3E02627A7241 Q41403094-30C4BB16-AFF0-4774-B3C2-3D2BF3E24A69 Q41822455-E2CF2E57-AC76-4C7C-8BC6-FA54A6152337 Q42778066-566F0A39-2546-4E5A-8F2A-7174402969E3

P2860

Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice.

http://www.wikidata.org/entity/Q45159120

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Soluble Flt-1 gene therapy ame ...... itial injury in diabetic mice.

@en

Soluble Flt-1 gene therapy ame ...... itial injury in diabetic mice.

@nl

type

label

Soluble Flt-1 gene therapy ame ...... itial injury in diabetic mice.

@en

Soluble Flt-1 gene therapy ame ...... itial injury in diabetic mice.

@nl

prefLabel

Soluble Flt-1 gene therapy ame ...... itial injury in diabetic mice.

@en

Soluble Flt-1 gene therapy ame ...... itial injury in diabetic mice.

@nl

P1433

Q45159120-2E235368-F080-4B9F-B972-D6F66C5FF52C

P1476

Q45159120-A98D806C-48D0-460C-B413-A7DDE266459D

P2093

Q45159120-267D75C6-3EB3-49D8-9B51-4E5C47BDC796

Q45159120-4F2E3E02-06F4-44F4-B3FA-2F26AE264838

Q45159120-686C57F8-8906-490A-9147-ED02C9694B04

Q45159120-873EF3E1-D76D-450F-B64D-997AA120DC5B

Q45159120-96025291-E0BB-4C2E-B5A1-C890929A7B5D

Q45159120-AD17D12B-AC7E-4923-BD71-1172BC88BBF3

Q45159120-BA7C7081-5B8E-43F4-BD2B-D03954B276EF

Q45159120-CEA34D1B-511B-4559-A8ED-606BFE9F936B

P2860

Q45159120-07F0C369-ADE7-44E7-9A16-4DE6D2F9DEED

Q45159120-0AE4A9CB-896A-4E6E-9451-D540A18F451D

Q45159120-1285CF75-ED9D-42E4-A400-3ECFDFDB9DD2

Q45159120-1F7D05FC-FA33-4F8D-9D6C-274AFC28AB8B

Q45159120-22C5AB8D-1352-46FA-B165-2CCEA014CAB3

Q45159120-28F40264-FF7F-4112-AEAA-251CA255AC90

Q45159120-298741ED-94B2-4508-BD51-6F421FC09F89

Q45159120-2C56342D-C824-44B4-B674-217D2D4E75B7

Q45159120-2C58B3FA-DCDC-48E7-88CF-A7F1E7981FDD

Q45159120-2D82C164-CA67-4D17-835D-00F570AEEA4C

P304

Q45159120-B1C418E7-381E-4400-B959-4DC8902BF795

P31

Q45159120-CAE70983-CC74-4F90-9ABB-F72020B50AF5

P356

Q45159120-B556E09F-3921-4306-867B-05B502291C64

P433

Q45159120-C4BFAFF7-B5DD-48DA-B065-98FA238F9A3B

P478

Q45159120-627FF470-6581-4E9B-8B40-A98072E1E98A

P50

Q45159120-C7C7C95D-58AF-4343-B1AE-6E7F94E911AB

P577

Q45159120-90179E5D-867E-4487-A38A-5AED4418327D

P698

Q45159120-FD421E7D-7927-4A95-B8FA-CC746BF9B757

P921

Q45159120-2DCDDB72-FF41-47F6-9296-4E8838EA91B0

P356

AJPRENAL.00377.2009

P1433

American Journal of Physiology - Renal Physiology

P1476

Soluble Flt-1 gene therapy ame ...... itial injury in diabetic mice.

@en

P2093

Byron P Croker

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

Maria Grant

http://www.w3.org/2001/XMLSchema#string

Qiuhong Li

http://www.w3.org/2001/XMLSchema#string

Takahiko Nakagawa

http://www.w3.org/2001/XMLSchema#string

Takahiro Nakayama

http://www.w3.org/2001/XMLSchema#string

Tomoki Kosugi

http://www.w3.org/2001/XMLSchema#string

Vince A Chiodo

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy.

High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors

Diabetic kidney disease in the db/db mouse.

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions

Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease.

Downregulation of p22phox in retinal pigment epithelial cells inhibits choroidal neovascularization in mice

P304

F609-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPRENAL.00377.2009

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

298

http://www.w3.org/2001/XMLSchema#string

P50

Martha Campbell-Thompson

P577

2009-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20015944

http://www.w3.org/2001/XMLSchema#string

P921